Teriparatide Biosimilar(Genetech Pharmaceutical)

左滑切换英文版新闻稿 Swipe left to switch to the English version of the press release 二零二六年八月二十六日 – 香港 综合性生物制药公司 — 联康生物科技集团有限公司（「联康集团」或「本公司」，连同其附属公司统称「本集团」，股份代号：0690）欣然宣布本集团截至二零二六年六月三十日止六个月(「期内」）的中期业绩。 PART.01 二零二六年上半年取得之重大成就 期内，本集团取得了一系列成就，在已上市产品及创新的生物制剂方面均取得良好成绩。主要取得的成就如下: 01 期内，本集团收益约为273.8 百万港元，纯利约为31.2百万港元。现金流维持稳健，经营现金流约为11.4百万港元。尽管监管政策调整、研发、商业化及国际扩张的前期投入令盈利短暂受压，本集团仍保持盈利及财务稳健，展现营运韧性。 02 于二零二六年六月三十日，权益总额增加8.6%至约448.7百万港元，资本基础持续巩固。负债权益比率改善至34.9%，显示积极去杠杆及审慎管理资本。本集团维持净现金状态，现金比率维持1倍以上，反映现金及现金等价物远超短期负债。充裕的流动资金为本集团提供了坚实的财务支持，使集团能够有效应对期内利润的短期波动，并支持未来研发投入、产品商业化及国际市场拓展。 03 博固泰®收益按年增长39.3%，主要归因于该创新骨质疏松症疗法在中国医学界及患者中的持续市场开发及互动。截至二零二六年第一季度，博固泰®于中国特立帕肽产品中整体市场份额排名第二，并于零售渠道排名第一，全国销售额超越原研品牌，于商业化上市约两年内取得该等市场地位。 04 期内，本集团正式启动高端系列GeneQueens®的商业上市及市场推广，进一步丰富功能性护肤及医美术后护理产品组合。该高端系列采用专有三蛋白复合物（纤连蛋白、III型胶原蛋白及XVII型胶原蛋白），各成分均以1,000 ppm的高浓度调配，以优化细胞修复及抗衰老功效。此里程碑展现本集团加速合成生物学平台商业化的具体进展。 05 本集团正推进BMP–2再生医学项目的开发，利用其专有ECO-KSFA®平台，本集团已成功建立BMP–2原料药的高产量生产工艺，而BMP–2为再生医学中广泛应用于脊柱融合及骨缺损重建的重要生长因子。期内，本集团完成BMP–2原料药的中试规模生产工艺，并启动缓释凝胶配方的开发，为最终确定产品临床剂型奠定稳固基础。 06 新一代仿制抗真菌药物硫酸艾沙康唑胶囊已完成监管机构要求的所有补充研究，本集团正准备于二零二六年下半年向药品审评中心(CDE)提交相应文件。为支持未来商业化，本集团已委托建设一条专为该产品设计的专用生产线，并与优质原料药供货商建立战略合作伙伴关系，以确保商业化所需的可靠产能及供应。 PART.02 中期业绩 二零二六年上半年是本集团的战略转型期，其特点为产品组合优化以及渠道及市场准入的拓展。期内收入短期内受到匹纳普®因战略性集中带量采购价格调整所带来的影响，金因肽®亦受到一定程度的影响。此外，最新生物制品增值税政策的实施亦对产品净售价产生结构性影响。期内，本集团录得收益约273.8百万港元，按年下跌11.7%。 博固泰®收益由约65.6百万港元显著增加至约91.4百万港元，增幅为39.3%。博舒泰®收益由约6.1百万港元增加50.8%至约9.2百万港元。金因肽®收益由约107.8百万港元减少12.3%至约94.5百万港元。销量录得高单位数按年增长，反映持续强劲的需求以及扩大医院准入及处方基础的初步效益。金因舒®收益按年增加1.6%，由约18.5百万港元增至约18.8百万港元。匹纳普®期内收益由约108.9 百万港元减少47.1%至约57.6百万港元。尽管产品组合数量有限且营销及分销团队持续优化中，肌颜态®收益由约1.3百万港元增至约2.2百万港元，期内按年增长69.2%。本集团新推出的医疗器械产品金因敷®及金因康®（地夸磷索钠滴眼液）于期内并无重大收益贡献。本集团正积极拓展数字及社交媒体平台的布局，以提升金因敷®的品牌知名度，同时推进金因康®于院外渠道的拓展，加快产品市场渗透。 毛利约为222.7百万港元，较二零二五年上半年的约254.1百万港元减少12.4%，而毛利率维持稳定于81.3%。期内利润按年减少59.0%至约31.2百万港元。减少主要反映本集团战略转型期间的短期盈利压力，包括若干核心产品定价调整及增值税相关价格影响导致毛利绝对值下降，以及商业化、新产品上市、管线开发及国际扩张的持续投入。每股盈利约为0.52港仙，而二零二五年上半年为1.27 港仙。 PART.03 展望 凭借二零二六年上半年在商业化及研发方面的策略性投入，本集团进入下半年时已具备有利条件加速业务转型。随着仿制药在产品组合中持续让位于毛利率较高的生物制药，此变化的收益组合预期长远将带来持续的毛利率改善。随着生物制药首次获国家列为新兴支柱产业，本集团将持续提升创新能力、扩大商业化布局，把握行业高速发展带来的市场机遇。 联康生物科技集团主席梁国龙先生表示： 「二零二六年上半年，集团面对充满挑战的经营环境，但我们认为，这正是迈向更多元化产品组合及全渠道商业化布局的重要转型阶段。期内，我们持续完善商业化平台建设，进一步提升渠道覆盖的广度与深度，同时稳步推进多项创新产品管线的研发进程。我们持续落实全渠道策略，建立覆盖公立医院、分销商网络、零售药房及数字电商平台的销售网络，进一步提升产品在中国市场的可及性，并持续向三、四线城市深化布局。同时，我们针对八款核心产品制定差异化的商业化策略，根据不同产品的市场特点及发展阶段，精准配置资源，持续提升市场竞争力。在巩固中国市场的同时，我们亦积极推进全球化布局。博固泰®海外商业化进程持续取得进展，其美国FDA监管申报工作亦稳步推进，标志着集团首个海外商业化产品迈出了重要一步。 研发方面，我们的产品管线持续取得积极进展，包括本集团专有的EGF/FGF复合凝胶、新一代BFS剂型金因舒®，以及BMP-2再生医疗产品等，均依托集团专有的ECO-KSFA®合成生物学平台及生物水凝胶技术平台。这些创新平台将持续支持集团在药品、医疗器械及医疗美容领域推出具差异化及高附加值的创新产品。展望未来，我们将继续以商业化能力、全球化布局及创新平台建设为核心驱动，持续提升企业竞争力，为患者、合作伙伴及股东创造可持续的长期价值。」 关于联康生物科技集团有限公司 联康生物科技集团有限公司是一家于2001年在香港联合交易所主板上市的创新型生物医药企业（股票代码：00690.HK），致力于以下一代合成生物学技术与复杂多肽创新，驱动再生医疗发展。本集团聚焦于骨骼/肌肉再生、皮肤再生、眼部再生及耳鼻喉（ENT）再生四大核心研究领域，构建了涵盖生物创新药、高值仿制药与医疗美容等板块的多元化产品管线。本集团分别于北京、东莞及深圳均设有GMP的生产基地，具备研发、生产及商业化销售的全链条能力。本集团致力于成为再生医学领域的全球领导者，重新定义科学如何修复与延展人类生命。 如欲了解更多信息，请联系：  ir@uni-bioscience.com - END - 欢迎扫码了解集团更多资讯 26 August 2026 – Hong Kong A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its interim results for the six months ended 30 June 2026 (the “Period”). PART.01 Key Accomplishments in the First Half of 2026 During the Period, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include: 01 During the Period, the Group’s revenue reached approximately HK$273.8 million, with net profit standing at approximately HK$31.2 million. Cash generation remained solid, with operating cash flow at approximately HK$11.4 million. Despite temporary earnings compression resulting from regulatory adjustments and front-loaded investments in R&D, commercialization, and international expansion, the Group demonstrated operational resilience by remaining profitable and financially strong. 02 As at 30 June 2026, total equity increased by 8.6% to approximately HK$448.7 million, reflecting a strengthened capital base. The debt-to-equity ratio improved to 34.9%, demonstrating active deleveraging and prudent capital stewardship. The Group remains in a net cash positive position, with a cash ratio well above 1, indicating that cash and cash equivalents significantly exceed near-term liabilities. This strong liquidity cushion enables the Group to comfortably absorb the temporary reduction in net profit during the Period without compromising its financial stability. Together, these strengths position the Group to support future R&D investment, commercialization initiatives, and international expansion. 03 Revenue of Bogutai® increased significantly by 39.3% year-on-year (“YoY”), driven by the ongoing market development and engagement with this innovative osteoporosis therapy within the medical community and among patients in China. As of the first quarter of 2026, Bogutai® ranked second in overall market share and first in the retail channel among teriparatide products in China. Its nationwide sales surpassing those of the originator brand, achieving these market positions within approximately two years of commercial launch. 04 During the Period, the Group officially commenced the commercial launch and market promotion of its high-end series, GeneQueens®, further enriching its portfolio in functional skincare and post-procedure medical aesthetics. The premium line incorporates a proprietary triple-protein complex (Fibronectin, Type III Collagen, and Type XVII Collagen), each formatted at a high concentration of 1,000 ppm to optimize cellular repair and anti-aging performance. This milestone demonstrates concrete progress in accelerating the commercialization of its synthetic biology platform. 05 The Group is advancing the development of its BMP-2 regenerative medicine program. Utilizing its proprietary ECO-KSFA® platform, the Group has successfully established a high-yield production process for BMP-2 API, a crucial growth factor in regenerative medicine widely applied in spinal fusion and bone defect reconstruction. During the Period, the Group completed pilot-scale manufacturing process for the BMP-2 drug substance and initiated development of a sustained-release gel formulation, laying a solid foundation for finalizing the product's clinical dosage form. 06 The next-generation generic antifungal drug, Isavuconazonium sulfate capsules, completed all supplementary studies required by the regulator and the Group is preparing to submit the corresponding documentation to the Center for Drug Evaluation (CDE) in the second half of 2026. To support future commercialization, the Group has commissioned a dedicated production line specifically designed for the product and established strategic partnerships with high-quality API suppliers to ensure reliable manufacturing capacity and supply for commercialization. PART.02 Interim Results The first half of 2026 marked a strategic transition period for the Group, characterized by portfolio optimization alongside expanding channel and market access. Revenue during the Period was temporarily impacted by strategic volume-based procurement (VBP) pricing adjustments for Pinup® and, to a lesser extent, GeneTime®, coupled with the structural impact of latest biologics value-added tax (VAT) policies on net selling price. For the Period, the Group recorded revenue of approximately HK$273.8 million, representing a decrease of 11.7% YoY. Revenue of Bogutai® increased significantly from approximately HK$65.6 million to approximately HK$91.4 million, representing an increase of 39.3%. Revenue of Boshutai® increased by 50.8% from approximately HK$6.1 million to approximately HK$9.2 million. GeneTime® recorded a decrease of 12.3% in revenue from approximately HK$107.8 million to approximately HK$94.5 million. Sales volume of GeneTime® achieved high-single-digit YoY growth, reflecting continued strong underlying demand and the initial benefits of broader hospital access and prescription-base expansion. GeneSoft® recorded a 1.6% YoY increase in revenue from approximately HK$18.5 million to approximately HK$18.8 million. Pinup® recorded a decrease of 47.1% in revenue from approximately HK$108.9 million to approximately HK$57.6 million. With a limited number of product portfolio and the ongoing optimization of its marketing and distribution teams, revenue from 肌顏態® increased from approximately HK$1.3 million to approximately HK$2.2 million, representing a 69.2% YoY growth. Revenue contribution from the Group’s newly launched medical device product 金因敷® and 金因康® (Diquafosol Sodium Eye Drops) were immaterial during the Period. The Group is expanding its digital and social media presence to raise 金因敷® brand awareness, while advancing targeted non-public channel expansion to accelerate 金因康® uptake. Gross profit was approximately HK$222.7 million, representing a decrease of 12.4% as compared with approximately HK$254.1 million for the first half of 2025, whereas as gross profit margin remained stable at 81.3%. Profit for the Period decreased by 59.0% YoY to approximately HK$31.2 million. The decrease primarily reflected short-term profitability pressure during the Group's strategic transformation, including lower absolute gross profit resulting from pricing adjustments for certain core products and the VAT-related pricing impact, together with continued investment in commercialization, new product launches, pipeline development, and international expansion. The earnings per share were approximately HK$0.52 cents, compared with HK$1.27 cents in the first half of 2025. PART.03 Prospects Through targeted commercial and R&D investments in the first half of 2026, the Group enters the second half well positioned to accelerate its business transformation. As generic therapies continue to yield ground to higher-margin biopharmaceuticals within the Group's portfolio, this evolving revenue mix is expected to deliver sustained margin expansion over the long term. With biopharmaceuticals recognized for the first time as an emerging pillar industry supported by the state, the Group is committed to growing its innovation capabilities and expanding its commercial reach to capture this growing market opportunity. Mr.Kingsley Leung, Chairman of Uni-Bio Science, commented,  “The first half of 2026 presented a challenging operating environment, which we view as a transitional period toward a more diversified and all-round range of product offerings and promotional channels. During the period, we made significant progress in strengthening both the breadth and depth of our commercial platform while advancing a robust pipeline of innovative therapies. Our omni-channel strategy, spanning public hospitals, an expanding distributor network, retail pharmacy locations, and leading e-commerce platforms, continues to broaden patient access across China, including deeper penetration into Tier-3 and Tier-4 cities. At the same time, we are executing a disciplined, product-specific commercialization approach, tailoring our strategies to the distinct market dynamics of each of our eight core products. Beyond our domestic base, we are accelerating our global ambitions. We are advancing Bogutai®'s international expansion, together with our ongoing U.S. FDA submission, an important step toward establishing our first overseas commercialized therapy. Our pipeline continues to advance meaningfully, from our proprietary EGF/FGF compound gel for wound care to next-generation BFS-based GeneSoft® formulations and our BMP-2 regenerative therapy, all underpinned by our proprietary ECO-KSFA® synthetic biology and Biological Hydrogel technology platforms. These innovation engines position us to continue delivering differentiated, high-value therapies across pharmaceuticals, medical devices, and medical aesthetics. We remain confident that our integrated strategy, combining commercial excellence, global expansion, and platform-driven innovation, will create sustainable long-term value for our patients, partners, and shareholders.” About Uni-Bio Science Group Limited Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001 (Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to be the global leader in regenerative medicine, redefining how science restores and extends human life. For further information, please contact:  ir@uni-bioscience.com - END - Welcome to scan the QR code to learn more about the group.